Celgene Virtual Programs

An opportunity for healthcare professionals to participate in a live informational speaker program with nationally recognized experts

Click the button below to learn more about upcoming live, interactive, promotional programs

Learn more about the following topics:

  • An overview of metastatic breast cancer and ABRAXANE as a treatment option
  • An overview of non-small cell lung cancer and ABRAXANE as a treatment option
  • ABRAXANE as a treatment option for metastatic adenocarcinoma of the pancreas

For assistance, please call 1-800-531-6204 or email admin@directconnectsupport.com.

These speaker programs are not accredited for CME. The speakers involved in the program are presenting on behalf of Celgene. The information they present is consistent with FDA guidelines.

Celgene Virtual Programs

An opportunity for healthcare professionals to participate in a live informational speaker program with nationally recognized experts

Learn more about the following topics:

  • An overview of metastatic breast cancer and ABRAXANE as a treatment option
  • An overview of non-small cell lung cancer and ABRAXANE as a treatment option
  • ABRAXANE as a treatment option for metastatic adenocarcinoma of the pancreas

Click the button below to learn more about upcoming live, interactive, promotional programs

For assistance, please call 1-800-531-6204 or email admin@directconnectsupport.com.

These speaker programs are not accredited for CME. The speakers involved in the program are presenting on behalf of Celgene. The information they present is consistent with FDA guidelines.

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine

INDICATIONS

ABRAXANE is indicated for:

  • The treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated
  • The first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy
  • The first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine